Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences, the maker of at-home colon cancer screening test Cologuard, said it will buy Cambridge, Massachusetts-based Thrive Earlier Detection Corp. for $2.15 billion in cash and stock.

On March 3, 2020, Exact Sciences announced completion of its acquisition of Paradigm Diagnostics, Inc. and Viomics, Inc., privately held companies based in Phoenix, AZ. According to Exact Sciences ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial ...

Exact Sciences is looking for talented people who are passionate about fighting cancer. For more information and to view a complete list of job openings, visit the company careers site.

Exact Sciences expects full-year 2025 revenue to be in the range of $3.03 billion to $3.09 billion. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

Exact Sciences plans to launch the new product in the second half of 2020. Exact Sciences thinks that it now has a total addressable market of $20 billion.